USD
+$0.00
(+0.00%
)At Close (As of Oct 21, 2025)
$26.84B
Market Cap
46.87
P/E Ratio
1.46
EPS
$93.25
52 Week High
$57.52
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $2.4B |
Total Revenue | $4B |
Cost Of Revenue | $1.6B |
Costof Goods And Services Sold | $1.6B |
Operating Income | $600M |
Selling General And Administrative | $1.1B |
Research And Development | $552M |
Operating Expenses | $1.8B |
Investment Income Net | - |
Net Interest Income | $115M |
Interest Income | $134M |
Interest Expense | $19M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $218M |
Income Before Tax | $709M |
Income Tax Expense | $133M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $576M |
Comprehensive Income Net Of Tax | - |
Ebit | $728M |
Ebitda | $946M |
Net Income | $576M |
Field | Value (USD) |
---|---|
Total Assets | $6.5B |
Total Current Assets | $4.3B |
Cash And Cash Equivalents At Carrying Value | $606M |
Cash And Short Term Investments | $606M |
Inventory | $543M |
Current Net Receivables | $1B |
Total Non Current Assets | $2.2B |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $103M |
Intangible Assets Excluding Goodwill | $103M |
Goodwill | $23M |
Investments | - |
Long Term Investments | $119M |
Short Term Investments | $2B |
Other Current Assets | $146M |
Other Non Current Assets | - |
Total Liabilities | $4.4B |
Total Current Liabilities | $2.9B |
Current Accounts Payable | $345M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $1.2B |
Total Non Current Liabilities | $1.4B |
Capital Lease Obligations | $146M |
Long Term Debt | $1.2B |
Current Long Term Debt | $1.2B |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $2.6B |
Other Current Liabilities | $1.3B |
Other Non Current Liabilities | $18M |
Total Shareholder Equity | $2.1B |
Treasury Stock | - |
Retained Earnings | $1.6B |
Common Stock | $400K |
Common Stock Shares Outstanding | $413M |
Field | Value (USD) |
---|---|
Operating Cashflow | $990M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $218M |
Capital Expenditures | $359M |
Change In Receivables | - |
Change In Inventory | $12M |
Profit Loss | - |
Cashflow From Investment | -$208M |
Cashflow From Financing | -$735M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | -$750M |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | $576M |
Field | Value (USD) |
---|---|
Gross Profit | $2.4B |
Total Revenue | $4B |
Cost Of Revenue | $1.6B |
Costof Goods And Services Sold | $1.6B |
Operating Income | $600M |
Selling General And Administrative | $1.1B |
Research And Development | $552M |
Operating Expenses | $1.8B |
Investment Income Net | - |
Net Interest Income | $115M |
Interest Income | $134M |
Interest Expense | $19M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $218M |
Income Before Tax | $709M |
Income Tax Expense | $133M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $576M |
Comprehensive Income Net Of Tax | - |
Ebit | $728M |
Ebitda | $946M |
Net Income | $576M |
Sector: HEALTHCARE
Industry: MEDICAL DEVICES
DexCom, Inc. is a prominent leader in diabetes care, renowned for its groundbreaking continuous glucose monitoring (CGM) systems that empower patients to manage their diabetes effectively. Headquartered in San Diego, California, with a strategic manufacturing facility in Mesa, Arizona, the company is dedicated to advancing diabetes management through innovative technology and exceptional product quality. As a pioneer in glucose monitoring, DexCom is actively expanding its global presence to meet the rising demand for effective diabetes solutions, positioning itself as a key player in the evolving healthcare landscape.